1. Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, et al. Antimicrobial-resistant pathogens associated with healthcareassociated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011-2014. Infect Control Hosp Epidemiol. 2016; 37:1288–1301.
Article
2. Omotola AM, Li Y, Martin ET, Alshabani K, Yadav D, Sarkar M, et al. Risk factors for and epidemiology of community-onset vancomycin-resistant Enterococcus faecalis in southeast Michigan. Am J Infect Control. 2013; 41:1244–1248.
Article
3. Elizaga ML, Weinstein RA, Hayden MK. Patients in long-term care facilities: a reservoir for vancomycin-resistant enterococci. Clin Infect Dis. 2002; 34:441–446.
Article
4. Byun SJ, Kang J. Risk factors and clinical outcomes for vancomycin-resistant Enterococcus colonization on intensive care unit admission. J Korean Acad Nurs. 2013; 43:287–295.
Article
5. Hong HK, Lee KS, Park SC, Chung EK, Park MR, Kim SC. Effects of infection control strategies & analysis of risk factors for vancomycin resistant enterococci. Qual Improv Health Care. 2013; 19:30–42.
6. Kwak YG, Choi JY, Yoo HM, Lee SO, Kim HB, Han SH, et al. Korean nosocomial infections surveillance system, intensive care unit module report: summary of data from July 2013 through June 2014. Korean J Nosocomial Infect Control. 2015; 20:49–60.
Article
7. Monteserin N, Larson E. Temporal trends and risk factors for healthcare-associated vancomycin-resistant enterococci in adults. J Hosp Infect. 2016; 94:236–241.
Article
8. Ford CD, Lopansri BK, Haydoura S, Snow G, Dascomb KK, Asch J, et al. Frequency, risk factors, and outcomes of vancomycin-resistant Enterococcus colonization and infection in patients with newly diagnosed acute leukemia: different patterns in patients with acute myelogenous and acute lymphoblastic leukemia. Infect Control Hosp Epidemiol. 2015; 36:47–53.
Article
9. Lee D, Park ES, Yong D, Choi JY, Lee K, Jee SH. Risk factors for prolonged carriage and reacquisition of vancomycin-resistant enterococci. Korean J Nosocomial Infect Control. 2015; 20:19–28.
Article
10. Yoon YK, Lee SE, Lee J, Kim HJ, Kim JY, Park DW, et al. Risk factors for prolonged carriage of vancomycin-resistant Enterococcus faecium among patients in intensive care units: a case-control study. J Antimicrob Chemother. 2011; 66:1831–1838.
Article
11. Kaki R, Yu Y, O\'Neill C, Lee C, Mertz D. Vancomycin-resistant Enterococcus (VRE) transmission and risk factors in contacts of VRE carriers. Infect Control Hosp Epidemiol. 2014; 35:876–879.
Article
12. Karki S, Houston L, Land G, Bass P, Kehoe R, Borrell S, et al. Prevalence and risk factors for VRE colonisation in a tertiary hospital in Melbourne, Australia: a cross sectional study. Antimicrob Resist Infect Control. 2012; 1:31.
Article
13. Muto CA, Giannetta ET, Durbin LJ, Simonton BM, Farr BM. Cost-effectiveness of perirectal surveillance cultures for controlling vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol. 2002; 23:429–435.
14. Perencevich EN, Fisman DN, Lipsitch M, Harris AD, Morris JG Jr, Smith DL. Projected benefits of active surveillance for vancomycin-resistant enterococci in intensive care units. Clin Infect Dis. 2004; 38:1108–1115.
Article
16. Abad C, Fearday A, Safdar N. Adverse effects of isolation in hospitalised patients: a systematic review. J Hosp Infect. 2010; 76:97–102.
Article
17. Kirkland KB, Weinstein JM. Adverse effects of contact isolation. Lancet. 1999; 354:1177–1178.
Article
18. Weber SG, Huang SS, Oriola S, Huskins WC, Noskin GA, Harriman K, et al. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: Position statement from the Joint SHEA and APIC Task Force. Am J Infect Control. 2007; 35:73–85.
Article
19. Karki S, Leder K, Cheng AC. Should we continue to isolate patients with vancomycin-resistant enterococci in hospitals? Med J Aust. 2015; 202:234–236.
Article